Therapeutic area intelligence for Mantle Cell Lymphoma with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Ibrutinib →

pirtobrutinib →

Venetoclax →

Recent signals(3)

ClinicalJuly 30, 2026

Ibrutinib and Rituximab Show Promise in Relapsed/Refractory Mantle Cell Lymphoma

A phase II trial is investigating the efficacy of ibrutinib and rituximab in treating relapsed or refractory mantle cell lymphoma.

ClinicalJuly 7, 2026

Phase 2 Study of Lisaftoclax and Pirtobrutinib in Relapsed Mantle Cell Lymphoma

A phase 2 study is underway to assess the efficacy and safety of lisaftoclax combined with pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma after BTK-targeted therapy.

ClinicalJune 10, 2026

Phase II Trial of Venetoclax and Rituximab in Older Patients With Mantle Cell Lymphoma

A Phase II trial is underway to evaluate the efficacy of venetoclax combined with rituximab in older patients with untreated mantle cell lymphoma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Mantle Cell Lymphoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.